Previous Close | 93.17 |
Open | 93.79 |
Bid | 93.01 x 0 |
Ask | 93.03 x 0 |
Day's Range | 92.56 - 93.83 |
52 Week Range | 79.21 - 94.52 |
Volume | |
Avg. Volume | 3,356,932 |
Market Cap | 189.717B |
Beta (5Y Monthly) | 0.47 |
PE Ratio (TTM) | 23.13 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.30 (3.54%) |
Ex-Dividend Date | Mar 07, 2024 |
1y Target Est | N/A |
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.